Algeta and Sanofi Extend Research Collaboration
News Oct 15, 2012
Algeta ASA has announced that its research collaboration with Sanofi (previously Genzyme) has been extended.
This collaboration, which was announced in April 2011, is focused on evaluating the potential of linking the alpha-emitter thorium-227 to a novel and proprietary antibody from Genzyme to create a tumor-targeting alpha-pharmaceutical (also known as a Targeted Thorium Conjugate, or TTC).
Over the past 12 months, Algeta and Genzyme have jointly pursued a defined research program and both have contributed resources and expertise to the collaboration.
The program and the encouraging results produced to date have been reviewed by Algeta and Sanofi (following its 2011 acquisition of Genzyme) and both parties have now decided that the collaboration should continue on the same basis for a further year.
Thomas Ramdahl, Executive Vice President and Chief Technology Officer at Algeta, said: “We have made significant progress in this collaboration with Genzyme and are delighted that it is to continue with the added antibody experience provided by the broader Sanofi team.”
Can You Eat Cells? Computer Model Predicts Organisms that Use PhagocytosisNews
A computer model developed by Museum researchers may provide new insight into the origins of phagocytosis, the process by which single-celled organisms “eat” other cells as a means of absorbing nutrients or eliminating pathogens.READ MORE
‘Lipid Asymmetry’ Plays Key Role in Activating Immune CellsNews
Regulating the lipid and physical asymmetry of a cell’s membrane is critical to immune cell function, and researchers have now shown that by preventing loss of membrane asymmetry it’s possible to control the immune response.READ MORE
Studying Ebola-Host Cell Interaction Helps Find Targets for Antiviral DrugsNews
In some ways, the Ebola virus operates like a vampire; only after it is politely invited in to a host cell does it take up the task of destroying everything in its path. In a new study researchers seek to elucidate quantitatively the biomechanical mechanism of Ebola-host cell interaction, providing potential new targets for antiviral drug development.READ MORE
Comments | 0 ADD COMMENT
Next Gen Regenerative Medicine & Tissue Engineering
May 29 - May 30, 2018